ĐÁNH GIÁ KẾT QUẢ SAU 6 THÁNG ĐIỀU TRỊ TENOFOVIR ALAFENAMIDE (TAF) Ở BỆNH NHÂN VIÊM GAN VI RÚT B MẠN

Abstract

Tenofovir alafenamide (TAF) - a prodrug of Tenofovir - is a hepatitis B virus inhibitor which has the same efficacy for hepatitis B virus as TDF but lower incidence of adverse side effects on kidney and bone.

Objective: Evaluate the effectiveness of TAF in chronic hepatitis B patients after 6 months of treatment.

Methods: Patients over 18 years old who were diagnosed with chronic hepatitis B according AASLD 2009 criteria were treated with a tablet of TAF daily. These patients were tested after 3 months and 6 months of treatment.

Results: Among 49 patients, there were 29 (59.2%) patients that were first time confirmed with chronic hepatitis B. 87.8% of them had ALT above 80 U/L while 83.7% had HBV - DNA above 6 log copies/ml. After 6 months of treatment, 69.4% of patients had a normal level of ALT. However, the proportion of ALT normalization varied as it was based on the initial level of ALT of the individual patient: 100%; 66.7% and 33.3%, with the initial level of ALT > 200U/L, 80 - 200U/L and ≤ 80U/L, respectively. In addition, there was no difference in ALT normalization between the HBeAg(-) and the HBeAg(+) group but 11.1% of patients in the HBeAg(+) group achieved seroconversion. In terms of HBV - DNA level, it was undetectable in 55.3% of the patients after 6 months of treatment. It was also notable that the number of patients who had undetectable HBV - DNA levels in the HBeAg(-) group was significantly higher than those in the HBeAg(+) group, 77.3% versus 37%, respectively (p < 0.05). Conc lusion: TAF was demonstrated as an effective antiviral drug for hepatitis B. After 6 months of treatment with TAF, the viral response in HBeAg(-) is better than in HBeAg(+) group.